Your browser doesn't support javascript.
loading
Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma.
Özogul, Ece; Montaner, Anna; Pol, Melina; Frigola, Gerard; Balagué, Olga; Syrykh, Charlotte; Bousquets-Muñoz, Pablo; Royo, Romina; Fontaine, Juliette; Traverse-Glehen, Alexandra; Bühler, Marco M; Giudici, Luca; Roncador, Marco; Zenz, Thorsten; Carras, Sylvain; Valmary-Degano, Severine; de Leval, Laurence; Bosch-Schips, Jan; Climent, Fina; Salmeron-Villalobos, Julia; Bashiri, Melika; Ruiz-Gaspà, Silvia; Costa, Dolors; Beà, Sílvia; Salaverria, Itziar; Giné, Eva; Quintanilla-Martinez, Leticia; Brousset, Pierre; Raffeld, Mark; Jaffe, Elaine S; Puente, Xose S; López, Cristina; Nadeu, Ferran; Campo, Elias.
Afiliação
  • Özogul E; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Montaner A; Pathology Department, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  • Pol M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Frigola G; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Balagué O; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Syrykh C; Hospital Clínic de Barcelona, Barcelona, Spain.
  • Bousquets-Muñoz P; University of Barcelona, Barcelona, Spain.
  • Royo R; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Fontaine J; Hospital Clínic de Barcelona, Barcelona, Spain.
  • Traverse-Glehen A; University of Barcelona, Barcelona, Spain.
  • Bühler MM; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Giudici L; Toulouse University Hospital Center, Cancer Institute University of Toulouse-Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse, CEDEX 9, France.
  • Roncador M; INSERM UMR1037 Cancer Research Center of Toulouse (CRCT), ERL 5294 National Center for Scientific Research (CNRS), University of Toulouse III Paul-Sabatier, Toulouse, France.
  • Zenz T; Institut Carnot Lymphome CALYM, Laboratoire d'Excellence 'TOUCAN', Toulouse, France.
  • Carras S; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Valmary-Degano S; Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, 33006, Oviedo, Spain.
  • de Leval L; Barcelona Supercomputer Center, Barcelona, Spain.
  • Bosch-Schips J; Hopital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
  • Climent F; Hopital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
  • Salmeron-Villalobos J; University Hospital Zurich, Zurich, Switzerland.
  • Bashiri M; Institute of Pathology, Ente Ospedaliero Cantonale (EOC), 6900, Locarno, Switzerland.
  • Ruiz-Gaspà S; University Hospital Zurich, Zurich, Switzerland.
  • Costa D; University Hospital Zurich, Zurich, Switzerland.
  • Beà S; Grenoble Alpes University, CHU Grenoble Alpes and INSERMN UMR 1209/CNRS 5309, Institute for Advanced Biosciences, Grenoble, France.
  • Salaverria I; Grenoble Alpes University, CHU Grenoble Alpes and INSERMN UMR 1209/CNRS 5309, Institute for Advanced Biosciences, Grenoble, France.
  • Giné E; Lausanne University Hospital and Lausanne University, Lausanne, Switzerland.
  • Quintanilla-Martinez L; Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Spain.
  • Brousset P; Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Spain.
  • Raffeld M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Jaffe ES; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Puente XS; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • López C; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Nadeu F; Hospital Clínic de Barcelona, Barcelona, Spain.
  • Campo E; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Blood Cancer J ; 14(1): 166, 2024 Sep 23.
Article em En | MEDLINE | ID: mdl-39313500
ABSTRACT
Mantle cell lymphoma (MCL) is genetically characterized by the IGCCND1 translocation mediated by an aberrant V(D)J rearrangement. CCND1 translocations and overexpression have been identified in occasional aggressive B-cell lymphomas with unusual features for MCL. The mechanism generating CCND1 rearrangements in these tumors and their genomic profile are not known. We have reconstructed the IGCCND1 translocations and the genomic profile of 13 SOX11-negative aggressive B-cell lymphomas using whole genome/exome and target sequencing. The mechanism behind the translocation was an aberrant V(D)J rearrangement in three tumors and by an anomalous IGH class-switch recombination (CSR) or somatic hypermutation (SHM) mechanism in ten. The tumors with a V(D)J-mediated translocation were two blastoid MCL and one high-grade B-cell lymphoma. None of them had a mutational profile suggestive of DLBCL. The ten tumors with CSR/SHM-mediated IGHCCND1 were mainly large B-cell lymphomas, with mutated genes commonly seen in DLBCL and BCL6 rearrangements in 6. Two cases, which transformed from marginal zone lymphomas, carried mutations in KLF2, TNFAIP3 and KMT2D. These findings expand the spectrum of tumors carrying CCND1 rearrangement that may occur as a secondary event in DLBCL mediated by aberrant CSR/SHM and associated with a mutational profile different from that of MCL.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Ciclina D1 / Linfoma de Célula do Manto Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Ciclina D1 / Linfoma de Célula do Manto Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article